Table 1. Clinical features of patients.
| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6/sibling of patient 5 |
| Age (year)/sex | 4/M | 10/F | 6/F | 8/M | 11/M | 9/F |
| Age of initial symptoms | 4 month | 2 year | 5 year | 9 month | Infancy | Infancy |
| Age of diagnosis (year) | 1 | 9 | 6 | 6 | 10 | 8 |
| Fever | + | - | - | - | - | - |
| Arthritis | - | + | + | + | + | + |
| Dermatitis | + | - | + | - | - | - |
| Uveitis | - | - | - | - | - | - |
| Tenosynovitis | - | + | + | + | + | + |
| Camptodactyly | - | + | + | + | + | + |
| Kidney | - | + | - | - | - | - |
| Liver | + | - | - | - | - | |
| LAP | + | - | - | - | - | - |
| Lung | - | - | - | - | - | - |
| High APR | + | + | - | - | - | + |
| High ACE | - | - | - | - | - | - |
| Mutations | P268S/V955I | M513T/- | R702W/SNP8 | H343Y/- | V955I/M491L | M491L |
| MEFV mutations | R761H/- | - | - | E148Q/- | E148Q/- | - |
| Previous treatment | Steroid, MTX, | Steroid, MTX, | NSAI, MTX | NSAI, MTX, | NSAI, MTX | NSAI, MTX |
| ANA, ADA, | ETA, TOS | ETA, TOS, | ||||
| IFN | ADA, INF, CAN | |||||
| Current treatment | LDS, CAN | MTX, INF | MTX | LDS, Siklosporin | MTX, INF | MTX, INF |
| LAP: Lymphadenopathy; APR: Acute Phase Reactans; ACE: Angiotensin converting enzyme; MEFV: Mediterranean fever; MTX: Methotrexate; ANA: Anakinra; ADA: Adalimumab; IFN: Infliximab; ETA: Etanercept; TOS: Tosilizumab; NSAI: Non-steroid anti-inflammatory drugs; CAN: Canakinumab; LDS: Low dose steroid. | ||||||